Reynolds E W, Conely E T, Vranicar M
Division of Neonatology, Department of Pediatrics, University of Kentucky College of Medicine, Kentucky Children's Hospital, 800 Rose Street, MS 477, Lexington, KY 40536, USA.
Pediatr Cardiol. 2007 May-Jun;28(3):229-33. doi: 10.1007/s00246-006-0064-6. Epub 2007 Mar 20.
Nesiritide is a synthetic form of B-type natriuretic peptide. It is approved for the treatment of acute exacerbations of congestive heart failure in hospitalized adult patients. It is currently under investigation for use in other settings and other patient populations. This article describes administration of nesiritide to an infant patient with severe pulmonary hypertension and cor pulmonale. No adverse reactions occurred during administration of the drug. Specifically, there was no hypertension, vomiting, arrhythmia, or changes in renal function. No changes in renal function occurred in the months subsequent to treatment. This case report illustrates that nesiritide can be safely administered to critically ill infants with pulmonary hypertension and cor pulmonale. Our patient experienced a decrease in pulmonary pressure and improved clinical condition during and after the infusion. However, further study is required to fully evaluate the safety and efficacy of nesiritide for these patients.
奈西立肽是B型利钠肽的一种合成形式。它被批准用于治疗住院成年患者的充血性心力衰竭急性加重。目前正在研究其在其他情况和其他患者群体中的应用。本文描述了对一名患有严重肺动脉高压和肺心病的婴儿患者使用奈西立肽的情况。用药期间未发生不良反应。具体而言,没有出现高血压、呕吐、心律失常或肾功能变化。治疗后的几个月里肾功能也没有变化。本病例报告表明,奈西立肽可安全用于患有肺动脉高压和肺心病的危重症婴儿。我们的患者在输注期间及之后肺动脉压力降低,临床状况改善。然而,需要进一步研究以全面评估奈西立肽对这些患者的安全性和有效性。